Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;7(Suppl 4):S308-S311.
doi: 10.21037/tlcr.2018.12.11.

Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer

Chen Zhao  1 , Nobuyuki Takahashi  1 , Arun Rajan  1
Affiliations
Editorial

Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer

Chen Zhao et al. Transl Lung Cancer Res. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Possible treatment strategy for SCLC based on SLFN11 expression. Patients with high SLFN11 expression level (H score ≥1) could potentially benefit from combination of an alkylating agent and a PARP inhibitor. For patients with SLFN11-deficient tumors, adding EZH2 inhibitors, HDAC inhibitors, DNA demethylating agents or ATR inhibitors to cytotoxic chemotherapy or PARP inhibitors can potentially overcome resistance to DNA damaging therapies caused by SLFN11 deficiency. SCLC, small cell lung cancer; PARP, Poly (ADP-ribose) polymerase; HDAC, histone deacetylase. (This figure was created with BioRender.)
See this image and copyright information in PMC

Comment on

References

    1. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 2018;7:69-79. 10.21037/tlcr.2018.01.16 - DOI - PMC - PubMed
    1. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7. 10.1200/JCO.2006.06.5821 - DOI - PubMed
    1. Green RA, Humphrey E, Close H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969;46:516-25. 10.1016/0002-9343(69)90071-0 - DOI - PubMed
    1. Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012;18:1138-45. 10.1158/1078-0432.CCR-11-2059 - DOI - PubMed
    1. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52:25-33. 10.1016/j.phrs.2005.02.010 - DOI - PubMed

LinkOut - more resources